Jennifer Ornelas
Dermatology · Sacramento, CANPI 1013332451
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,400 of the $102,850 with a category attached, or 64.6%. Organon accounts for 70.6% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $76,247, more than ten times the $604 reported in 2019. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 420 payments — averaging $244.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$73K
- Verrica Pharmaceuticals Inc.$20K
- LEO Pharma Inc.$2K
- AbbVie$1K
- Incyte Corporation$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $5K from 22 others
Across 529 payments — averaging $2194.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$389K
- Dermavant Sciences, Inc.$374K
- AbbVie$297K
- Sanofi US Services Inc.$101K
What the payments were for
- Consulting fees$10,08010%
- Speaking & faculty fees$66,40065%
- Travel & lodging$14,76714%
- Food & beverage$11,51911%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 56 | $72,570 |
| Verrica Pharmaceuticals Inc. | 17 | $19,754 |
| LEO Pharma Inc. | 15 | $1,680 |
| AbbVie(2 entities) | 45 | $1,266 |
| Incyte Corporation | 54 | $1,139 |
| Regeneron Healthcare Solutions, Inc. | 34 | $1,051 |
| Novartis | 37 | $722 |
| Amgen | 18 | $636 |
| Dermavant Sciences, Inc. | 12 | $563 |
| Arcutis Biotherapeutics, Inc. | 19 | $491 |
| UCB, Inc. | 17 | $483 |
| Sun Pharmaceutical Industries Inc. | 20 | $456 |
| Lilly USA, LLC | 21 | $408 |
| Sanofi | 12 | $365 |
| Johnson & Johnson | 7 | $296 |
| Galderma Laboratories, L.p. | 5 | $185 |
| Boehringer Ingelheim | 5 | $136 |
| Janssen Scientific Affairs, LLC | 2 | $133 |
| E.r. Squibb & Sons, L.L.C. | 4 | $116 |
| Pfizer | 6 | $99 |
| Botanix SB Inc | 4 | $81 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $64 |
| Biofrontera Inc. | 2 | $36 |
| Krystal Biotech Inc | 1 | $28 |
| Mimedx Group, Inc. | 1 | $28 |
| Cipher Pharmaceuticals US LLC | 1 | $26 |
| Biocon Biologics Inc | 1 | $26 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,850 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpzeluraRuxolitinib Phosphate | 24 | $46,680 |
| Tacrolimus | 24 | $3,095 |
| Clobetasol Propionate | 70 | $2,709 |
| Fluocinonide | 52 | $2,353 |
| Betamethasone Dipropionate | 43 | $1,882 |
| Ketoconazole | 111 | $1,631 |
| Fluorouracil | 21 | $1,514 |
| Clindamycin Phosphate | 45 | $1,479 |
| Triamcinolone Acetonide | 89 | $760 |
| Dutasteride | 15 | $655 |
| Doxycycline Monohydrate | 16 | $585 |
| Hydroxyzine Hcl | 28 | $448 |
| Hydrocortisone | 52 | $257 |
| Terbinafine Hcl | 15 | $164 |
| Mupirocin | 17 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $1,139 | $46,68024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.
Other dermatology in Sacramento
- Raja SivamaniSacramento$1.9M
- Emil TanghettiSacramento$800K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Tien NguyenFountain Valley$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.